Cardinal

US-based healthcare services firm Cardinal Health has completed the acquisition of Johnson & Johnson’s (J&J) cardiology and endovascular devices business Cordis, for $1.9bn.

The acquisition, which was first announced by the companies in March, will expand Cardinal’s portfolio of physician preference items, including cardiovascular, wound management, and orthopedics products.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company is helping customers standardise medical devices, while providing new solutions in supply chain management, inventory optimisation, and work flow tools and data to support effective management of the patient.

Cardinal Health chairman George Barrett said: "I’m extremely pleased to welcome our new Cordis colleagues to Cardinal Health.

"With an ageing population and the accompanying demand for less invasive medical treatments, health systems around the world are searching for the best ways to ensure the highest quality care."

"With an ageing population and the accompanying demand for less invasive medical treatments, health systems around the world are searching for the best ways to ensure the highest quality care in the most cost-effective way."

The combined business will now be able to offer high-quality, daily use products, trackable inventory and logistics and deep analytic capabilities that will result in a comprehensive offering for healthcare.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Cordis, which produces cardiology and endovascular devices, reported annual sales of $780m last year.

The company carries out operations in more than 50 countries, including the US, UK, China, Japan, Germany, Italy, France and Brazil.

Cardinal Health will continue to sell Cordis products under the Cordis brand name due to its strong brand equity. In collaboration with experts worldwide, Cordis develops and manufactures interventional vascular technology to treat millions of patients who suffer from vascular disease.

When all integration work and transitions are completed over the next few years, 3,000 employees from the acquired business will join Cardinal Health.

Cardinal Health is focused on producing medical and surgical products, including gloves, surgical apparel and fluid management products.


Image: Cardinal Health portfolio now includes Cordis SMART Vascular Stent systems. Photo: courtesy of Cardinal Health / PRNewswire.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact